☆ 4.4 Letter

The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis

AIDS (2011)

Get Full Text
Add to Collection

Journal

AIDS
Volume 25, Issue 18, Pages 2308-2310

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e32834d3cab

Keywords

-

Categories

Immunology Infectious Diseases Virology

Funding

  1. NIAID NIH HHS [R21 AI077304, R21 AI080353, AI080353, AI043638, R56 AI047745, P30 AI036214, AI077304, AI74621, P01 AI074621, U01 AI069432, U01 AI043638, AI69432, R21 AI047745, AI047745, AI36214, UM1 AI069432, R01 AI047745] Funding Source: Medline
  2. NIMH NIH HHS [R01 MH083552, P30 MH062512, MH083552, MH62512] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.